ReviewInflammopharmacology2026
Bridging neuroinflammation, oxidative stress, and neurogenesis: aromatic turmerone as a multifunctional modulator via NF-κB and Nrf2 pathways.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation and oxidative stress are central mechanisms driving neurodegenerative diseases, while impaired neurogenesis limits regeneration. Aromatic-turmerone (ar-turmerone), a bioactive sesquiterpenoid from Curcuma longa, has emerged as a multifunctional neuroprotective agent capable of modulating inflammatory and regenerative processes simultaneously. Evidence from in vitro and in vivo models demonstrates that ar-turmerone suppresses Toll-like receptor 4 (TLR4)-dependent NF-κB and MAPK signaling, thereby reducing microglial activation, nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and proinflammatory cytokines (TNF-α, IL-1β, IL-6). Concurrently, it activates the Nrf2/HO-1 antioxidant pathway and enhances cAMP/PKA-CREB signaling, restoring redox homeostasis and promoting neuronal survival. Importantly, ar-turmerone drives microglial polarization toward the M2 anti-inflammatory phenotype and stimulates neural stem cell (NSC) proliferation and neuronal differentiation in the subventricular zone and hippocampus. These dual anti-inflammatory and neurogenic actions position ar-turmerone as a unique bridge between neuroinflammation suppression and neuroregeneration enhancement. Recent structure-activity relationship studies further reveal that N-substituted amide and naphthyl derivatives exhibit superior inhibition of NO and TNF-α release and improved neuroprotective potency in Alzheimer's and Parkinson's disease models. Collectively, ar-turmerone represents a promising multi-target natural scaffold for developing therapeutics that counteract neurodegeneration by simultaneously modulating microglial activation, oxidative stress, and endogenous neurogenesis.
Indexed as
Identifiers
42098564What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.